As seen after intratumor cDCV therapy, there was a significant increase in CD8+ T-cells in the mice treated with systemic cDCV, which again supports the induction of an immune response and is significant, as cDCV efficacy has been shown to be associated with CD8+ T-cell activation and tumor infiltration [14]. Here, CD8A is linked to neoplasm.